Cora Capital Advisors LLC Decreases Holdings in Johnson & Johnson (NYSE:JNJ)

Cora Capital Advisors LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 29.2% in the 4th quarter, HoldingsChannel reports. The fund owned 2,994 shares of the company’s stock after selling 1,236 shares during the period. Cora Capital Advisors LLC’s holdings in Johnson & Johnson were worth $433,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Dark Forest Capital Management LP bought a new position in Johnson & Johnson in the 2nd quarter worth about $223,000. Invst LLC boosted its position in shares of Johnson & Johnson by 11.7% in the second quarter. Invst LLC now owns 2,083 shares of the company’s stock valued at $305,000 after acquiring an additional 218 shares during the period. Quarry LP purchased a new position in Johnson & Johnson during the second quarter valued at approximately $49,000. Gateway Wealth Partners LLC increased its holdings in Johnson & Johnson by 12.6% during the 2nd quarter. Gateway Wealth Partners LLC now owns 2,412 shares of the company’s stock worth $352,000 after acquiring an additional 270 shares during the period. Finally, Truist Financial Corp raised its position in shares of Johnson & Johnson by 4.9% in the second quarter. Truist Financial Corp now owns 2,122,856 shares of the company’s stock worth $310,277,000 after buying an additional 98,903 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ opened at $150.63 on Wednesday. The stock has a 50-day moving average price of $147.81 and a 200-day moving average price of $156.12. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market cap of $362.65 billion, a PE ratio of 22.65, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the company earned $2.29 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.29%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $170.44.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.